Oct. 1, 2025 – Intelerad has announced the next generation of InteleHeart, a reimagined, all-in-one cardiology platform that unifies viewing, reporting, analytics, and workflow orchestration in a single solution. By bringing fragmented systems together, InteleHeart gives cardiologists, clinical leaders and care teams a whole picture of patient cardiac health, enabling them to streamline operations and make faster, more confident decisions that improve patient outcomes. 

Medtronic Hybrid Ablation

Hypertension remains the leading modifiable driver of cardiovascular disease and premature death.1 Even with multiple drug classes available, nearly 70% of adults have uncontrolled blood pressure.2

Sept. 30, 2025 — Biograph and Caristo Diagnostics have announced a partnership for Biograph to become the first U.S. clinic to study a novel AI-based preventive cardiac marker in asymptomatic patients, by detecting coronary artery inflammation from cardiac CT scans.

Sept. 29, 2025 — Many studies have shown the inverse relationship between bone mineral density (BMD) — the gold standard measure for osteopenia/osteoporosis and coronary calcium (CAC) — a biomarker of heart attack and stroke risk. For example, mild (osteopenia) or more severe (osteoporosis) low BMD is associated with elevated CAC/cardiovascular disease (CVD) risk. A new NIH-funded long term longitudinal study stratifies this association — showing different levels of low BMD corresponding to different levels of elevated CAC.

Sept. 30, 2025 — Cleerly has announced that coverage policies from UnitedHealthcare and Cigna for Cleerly LABS advanced plaque analysis will go into effect Oct. 1, 2025. These landmark decisions mark a new era in cardiac care, bringing AI-guided quantitative coronary CT angiography (AI-QCT)/Coronary Plaque Analysis (AI-CPA) within reach of millions of Americans.

Starting Oct. 1, 2025, patients will have access through streamlined coverage criteria that mirrors Medicare's established local coverage determinations and EviCore’s recently updated guidelines.

Sept. 29, 2025 — Radiation therapy may offer a comparable and potentially safer alternative to repeat catheter ablation for patients with severe abnormal heart rhythms that can no longer be controlled with medication.

Sept. 29, 2025 — AngioSafe has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its flagship product, the Santreva-ATK Endovascular Revascularization Catheter, enabled by its proprietary Atheroplasty technology platform. Santreva-ATK also received CE marking in July 2025 and was successfully used in the first real-world patient procedures in Italy earlier this month.

Sept. 25, 2025 — Royal Philips has entered a national partnership in the United States with Optum Healthcare. The inclusion of Philips’ Mobile Cardiac Telemetry (MCOT) and Philips Extended Holter (ePatch) in Optum Healthcare's network is designed to enable earlier detection of cardiac conditions and timely clinical intervention.

Sept. 25, 2025 — Kardigan has introduced the three late-stage clinical programs leading its robust pipeline, each strategically chosen to advance the company’s mission of delivering multiple important medicines. These programs target the underlying drivers of specific types of dilated cardiomyopathy (DCM), acute severe hypertension (ASH) and calcific aortic valve stenosis (CAVS), where no treatments exist.

Sept. 24, 2025 — The Family Heart Foundation, a leading research and advocacy organization, has announced the online publication of recommendations from a multidisciplinary panel in the Journal of Pediatrics to promote the early identification of children living with familial hypercholesterolemia (FH). 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now